Ariad About
Ariad: Ariad is a biopharmaceutical company engaged in
developing
novel therapies for aggressive and advanced-staged disease for which current treatments
are inadequate. Their lead product candidate AP23573 is aimed to treat
solid tumors and hematologic malignancies. In parallel, they
are moving ahead with the further development of their pipeline of preclinical
programs: Preclinical Programs -- oncogenic kinase inhibitor program,
based on AP23464, to treat solid tumors and certain forms of leukemia and to block
the spread of cancer, a major cause of morbidity and mortality in cancer; and
their bone-targeted mTOR inhibitor program, based on AP23841, to treat cancer
that has spread to bone and to treat primary bone cancers, such as osteogenic
sarcomas. Pipeline
Chart and Product Development for Ariad Pipeline:
AP23573
Solid
tumors and blood malignancies mTOR
More on Ariad: